"This has got nothing to do with politics," David Allan, president and CEO of YM Biosciences Inc., likes to say about his firm's effort to win U.S. acceptance for a potential cancer blockbuster that originated in Cuba. "It's got everything to do with medicine, and getting a safe and benign drug to patients." Read More
